key: cord-0758246-o7c6hbnz
authors: Kulkarni, Anand V.; Kumar, Pramod; Tevethia, Harsh Vardhan; Premkumar, Madhumita; Arab, Juan Pablo; Candia, Roberto; Talukdar, Rupjyoti; Sharma, Mithun; Qi, Xiaolong; Rao, Padaki Nagaraja; Reddy, Duvvuru Nageshwar
title: Systematic review with meta‐analysis: liver manifestations and outcomes in COVID‐19
date: 2020-07-08
journal: Aliment Pharmacol Ther
DOI: 10.1111/apt.15916
sha: 5f88ab339d4389fad8fda7192a5b246fee645970
doc_id: 758246
cord_uid: o7c6hbnz

BACKGROUND: The incidence of elevated liver chemistries and the presence of the pre‐existing chronic liver disease (CLD) have been variably reported in COVID‐19. AIMS: To assess the prevalence of CLD, the incidence of elevated liver chemistries and the outcomes of patients with and without underlying CLD/elevated liver chemistries in COVID‐19. METHODS: A comprehensive search of electronic databases from 1 December 2019 to 24 April 2020 was done. We included studies reporting underlying CLD or elevated liver chemistries and patient outcomes in COVID‐19. RESULTS: 107 articles (n = 20 874 patients) were included for the systematic review. The pooled prevalence of underlying CLD was 3.6% (95% CI, 2.5‐5.1) among the 15 407 COVID‐19 patients. The pooled incidence of elevated liver chemistries in COVID‐19 was 23.1% (19.3‐27.3) at initial presentation. Additionally, 24.4% (13.5‐40) developed elevated liver chemistries during the illness. The pooled incidence of drug‐induced liver injury was 25.4% (14.2‐41.4). The pooled prevalence of CLD among 1587 severely infected patients was 3.9% (3%‐5.2%). The odds of developing severe COVID‐19 in CLD patients was 0.81 (0.31‐2.09; P = 0.67) compared to non‐CLD patients. COVID‐19 patients with elevated liver chemistries had increased risk of mortality (OR‐3.46 [2.42‐4.95, P < 0.001]) and severe disease (OR‐2.87 [95% CI, 2.29‐3.6, P < 0.001]) compared to patients without elevated liver chemistries. CONCLUSIONS: Elevated liver chemistries are common at presentation and during COVID‐19. The severity of elevated liver chemistries determines the outcome of COVID‐19. The presence of CLD does not alter the outcome of COVID‐19. Further studies are needed to analyse the outcomes of compensated and decompensated liver disease.

Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global health problem. Severe COVID-19 can lead to multi-organ failure and may be associated with high mortality. Age, severity of the infection and comorbidity are important predictors of poor outcomes in COVID-19. 1,2 However, pandemics may not affect all populations equally, and certain populations are particularly vulnerable. Chronic liver disease (CLD) is one such population with increasing burden worldwide. Moreover patients with cirrhosis, being immunocompromised, are expected to be more susceptible and have worse outcomes in viral illness. 3 The incidence of elevation in aminotransferases and/or bilirubin have been variably reported in COVID-19.

Previous reviews have analysed a limited number of studies. 4, 5 However, the incidence of elevated liver chemistries at initial presentation or during illness or the presence of pre-existing CLD on outcomes of COVID-19 has not been extensively reviewed so far. In this systematic review, we compiled all the data published and analysed the liver involvement in COVID-19, describing each variable of liver chemistries in COVID-19 and the effect of COVID-19 in patients with pre-existing CLD. We aimed to answer these questions:

(a) What is the prevalence of CLD in the global COVID-19 burden?;

(b) What is the incidence of elevated liver chemistries at initial presentation and during the illness in COVID-19?; and (c) What is the association of elevated liver chemistries and pre-existing CLD on clinical outcomes of COVID-19?

We followed the meta-analysis of observational studies in epidemiology (MOOSE) guidelines for data extraction and reporting. 6 Two independent reviewers performed a comprehensive search of electronic databases (by AVK and PK) including PUBMED, Excerpta Medica Database (EMBASE) and Scopus since 1 December 2019, to 24 April 2020. Search items included "SARS-CoV-2", "Coronavirus," "COVID-19", "Cirrhosis," "Liver." Articles on drugs causing liver injury was made till 30 April through google search engine. The details of the search strategy for PUBMED are reported in the Appendix 1.

The data were abstracted by two investigators independently (AVK and PK) based on the protocol priori, which was registered on Prospero (CRD42020181962). Case reports (of >2 patients), case series, cross-sectional studies, case-control studies, cohort studies (retrospective and prospective), quasi-randomised and randomised controlled trials that mentioned elevated liver chemistries in patients with COVID-19 were included irrespective of age and gestational status. Studies that did not report any data on liver chemistries or underlying CLD were excluded. Furthermore, experimental studies, studies describing the mechanism, review articles, virology studies, studies describing only the radiological features or studies describing the usage of artificial intelligence in COVID-19, epidemiology, transmission, and surveillance-related articles, editorials, investigations (testing)-related articles, guidelines, recommendations, unpublished data and management-related articles were excluded.

The following parameters were recorded: first author country of study, number of patients, age, gender, underlying CLD and their outcomes, percentage of patients with elevated liver chemistries (defined as elevation above the laboratory upper limit of normal) at initial presentation, percentage of patients developing elevated liver chemistries during the illness, number of patients with severe disease/non-severe disease, and percentage of patients developing drug-induced liver injury (DILI) and the implicated drug and lastly the mortality if reported.

We also noted the percentage of patients who presented with elevated liver chemistries separately for each variable, that is, bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), albumin and prothrombin time (PT). We took AST or ALT levels above 40 U/L (or the upper limit of normal for that laboratory) as elevated. The percentage of patients with elevated AST/ALT (whichever is higher) at initial presentation and during follow-up was recorded.

Percentage of patients with elevated liver chemistries in severely infected and non-severely infected, if reported, was recorded. We also recorded the percentage of patients with elevated liver chemistries at initial presentation and during illness in alive (survivor) and dead (non-survivor) patients of COVID-19. If none of the enzyme elevations was reported, then the percentage of patients presenting with hyperbilirubinaemia was recorded. Two individuals (HT and MP) again separately checked the abstracted data. Any discrepancy in the data was discussed and sorted. Articles not in English were converted using the online google translate tool and included for review. The converted data were confirmed by a Chinese native speaker (XQ).

Underlying CLD was defined as any pre-existing liver disease before the SARS-CoV-2 infection. 4 We took CLD/cirrhosis (due to any cause), chronic hepatitis B, chronic hepatitis C, non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis as the underlying liver disease. We used the definitions given by the authors of the primary studies to define the rise in enzyme levels for ALP, GGT and prothrombin prolongation. We considered any elevation in liver enzymes or total bilirubin after the initiation of the drugs as DILI in the absence of identified common causes of liver disease (viral, autoimmune, etc) by the primary authors. Severe liver injury was defined as any elevation of enzymes over three times ULN (upper limit of normal) and bilirubin over 2 ULN. 7 In general, we defined severe infection as per Chinese National Health Commission guidelines which defined severe infection as adult patients meeting any of the following criteria (a) respiratory rate ≥30 beats/min in a resting state; or (b) a mean oxygen saturation of ≤93%; or (c) an arterial blood oxygen partial pressure (PaO2)/oxygen concentration (FiO2) ≤300 mm Hg; (d) computed tomographic image showing significant lesion progression >50% within 24-48 hours or as per the authors of the primary studies. 8 We also included severe pneumonia as those patients satisfying one major criterion or ≥3 minor criteria of American Thoracic Society (ATS) guidelines for community-acquired pneumonia. 9 In the absence of such definitions, we considered patients with documented pneumonia requiring ICU care/oxygen support as severe disease.

The study outcome measures were: number of liver disease patients with COVID-19 and their outcomes (pre-existing CLD in COVID-19); the pooled incidence of elevated liver chemistries at initial presentation and during illness in COVID-19 and the effect of these elevated liver chemistries on the outcome of COVID-19; the incidence of AST/ALT elevation at initial presentation in COVID-19; the incidence of ALP/GGT elevation at initial presentation in COVID-19; the incidence of hyperbilirubinaemia/hypoalbuminaemia at initial presentation in COVID-19; the incidence of PT prolongation and the incidence of DILI in COVID-19 patients.

Two independent reviewers (AVK, PK) did the quality appraisal using the Appraisal tool for Cross-Sectional Studies (AXIS) checklist for cross-sectional studies and the Institute of Health Economics (IHE) checklist tool for case series. 10,11 AXIS checklist has a total of 20 points of which seven questions are related to the quality of reporting, seven related to study design and six questions are aimed to assess the bias in the study. IHE is a comprehensive checklist of quality of study which covers both the risk of bias and quality of reporting.

Randomised studies were assessed using the Cochrane collaboration tool. 12 New-castle Ottawa scale tool was used to assess the bias in case-control and cohort studies. 13 Any discrepancy in the study quality assessment was discussed, and the best score was decided after confirming with a third independent individual (PNR) who acted as the ombudsman.

A database was generated in Microsoft Excel, and meta-analysis was performed using the Comprehensive Meta-analysis package (Ver.

3.3.070; 2014). We expressed the percentages as the event rate and transformed the pooled data by Logit transformation method to assess the pooled incidence. The sample size (n) was entered, and the analysis was run. Studies with sample size <10 were excluded from the pooled meta-analysis. We included all patients irrespective of age, gender, comorbidity, type of infection (mild or severe) across different countries. And we also included pregnant patients.

Hence, we expected high heterogeneity and used the random model effect. We used the odds ratio to express the measured effect. For studies reporting the proportion of patients with elevated liver chemistries for two comparative groups, odds ratios were used to describe the difference between severe vs non-severe and survivor vs non-survivor groups. We assessed the statistical heterogeneity by visual inspection of forest plots, and using the Chi-squared and the I 2 statistics. A P value <0.10 was considered to indicate statistically significant heterogeneity. Q measure was used to evaluate the significance of heterogeneity and was considered statistically significant when P was <0.1. Publication bias was assessed by funnel plot asymmetry and quantified using Egger's intercept. 

A total of 4213 articles were screened for eligibility. (Figure 1 Hong Kong 76 and Iran. 66 One was a multicentre trial on remdesivir conducted simultaneously at USA, Japan, Italy, Austria, France, Germany, Netherlands, Spain and Canada. 93 A total of 7627 patients were reported from countries other than China. (Figure 2 ).

A total of 409 patients had underlying liver disease among the 50 articles which reported it. 7 (Table 1) There was no mention about the decompensations of liver disease in any of the articles, although one of the studies did mention the cause of death as variceal bleed in a SARS-CoV-2-infected patient. 48 The pooled prevalence of CLD among 1587 severely infected patients was 3.9% (3%-5.2%) among 18 articles which reported it . 14, 16, 27, 34, 36, 39, 41, 43, 50, 57, 67, 77, 85, 87, 91, 96, 99, 101 The pooled prevalence of CLD among 2699 non-severely infected patients was 3.1%

(2.5-3.9) among 19 articles which reported it. 16, 27, 34, 36, 38, 41, 43, 44, 50, 67, 77, 80, 85, 87, 91, 95, 96, 99, 101 (Figure S1A ,B) The prevalence of CLD was 4.7% (95% CI, 2.9-7.7) among 326 non-survivors reported in five articles. 48, 52, 63, 88, 92 The prevalence of CLD was 3.6% (95% CI, 2-6.6) amongst 292 survivors reported in four articles. 38 patients (CLD) hence we could not meta-analyse the mortality difference among CLD and non-CLD patients. The incidence of mortality among 11 hepatitis B patients was 45.5% which reported it. 57 For the pooled meta-analysis, we excluded studies reporting the incidence of elevated liver chemistries among <10 patie nts. 24 did not have any adverse effects on foetal or maternal outcomes.

Of the 58 patients who had gastrointestinal (GI) manifestations in COVID-19, elevated liver chemistries were the most common GI manifestation, followed by diarrhoea. 84

Forty-six studies reported mortality. 14 The incidence of elevated liver chemistries in non-severe COVID- The definitions of severely infected and non-severely infected in the included studies are explained in Table S4 . While the incidence was 41.1% (95% CI, 33.1-49.5) in severely infected patients among the nine articles, which reported 780 sick patients. 16, 17, 29, 34, 50, 67, 91, 102 ( Figure S6 ) Severely infected patients had higher odds of presenting with elevated liver chemistries, that is, OR-2.87 (95% CI, 2.29-3.6, P < 0.001) among nine articles which compared severe (n = 690) and

non-severe patients (n = 1290) ( Figure S7 ). 16 

The incidence of elevated liver chemistries during illness was 24 

The pooled incidence of AST elevation was 22.5% (95% CI, 18. Figure S10 ).

The pooled incidence of ALT elevation was 20.1% (95% CI, 16.8- ( Figure S11 ).

The incidence of hyperbilirubinaemia was 13.4% (95% Figure S12A ).

Eleven articles reported prolongation in PT in adults ranging from 2.1% to 58% at initial presentation. The pooled incidence of PT prolongation was 9.7% (95% CI, 4.6%-19.2%) among the 11 articles which reported it (n = 1739). 2, 21, 32, 36, 49, 70, 71, 79, 82, 86, 92 The incidence of PT prolongation was 7.1% (95% CI, 1%-37%) in only 1 article, which reported PT prolongation amongst children. 79 The pooled incidence of PT prolongation was 9.5% (95% CI, 4.7%-18.6%). ( Figure S12B ).

Alkaline phosphatase elevation was reported among 5 articles (n = 918 patients). The incidence of ALP elevation was 6.1% (95% 

In total, 12 articles reported DILI. 7 Hyperbilirubinaemia was the most frequent adverse effect of LPV/r, followed by elevated aminotransferases. 7, 15, 114 While remdesivir frequently led to elevated aminotransferases. 64, 118 In some studies DILI was attributed to more than one drug. 65 The incidence of adverse effects were reported in 66% of remdesivir recipients versus 64% in placebo recipients. Hyperbilirubinaemia developed in 10% (15/155) and AST elevation in 5% (7/155) in remdesivir group. 93 Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early. 93 Interestingly, 28% in remdesivir group and 38% in the placebo group had received concomitant LPV/r. Three patients had to discontinue due to deranged liver function tests, that is, elevated ALT (2 patients) and bilirubin (1 patient). In another multicentre study of 53 patients, a total of 23% (12/53) developed elevated aminotransferases, and two patients discontinued the drug due to elevated aminotransferase. 118

We included a vast number of trials ranging from case series to large studies which described 5700 patients with different age groups. There was no publication bias when the studies report- Table S5 .

In this systematic review, we evaluated the incidence of elevated liver chemistries in patients with COVID-19. The salient features noted in our exhaustive review of 107 studies from various countries are: (a) Note: Antivirals: umifenovir, oseltamivir, acyclovir in Ref. [7] . The study by Lin et al 84 has not mentioned the drugs.

Antibiotics: levofloxacin, azithromycin, cephalosporin in Ref. [7] . The study by Lin et al 84 has not mentioned the drugs.

Abbreviations: CI, confidence interval; LPV/r, lopinavir/ritonavir. TA B L E 2 Incidence of liver injury for different drugs F I G U R E 5 Funnel plot of the studies included for (A) prevalence of chronic liver disease (B) incidence of elevated liver chemistries at initial presentation (C) incidence of elevated liver chemistries during the illness (D) incidence of drug-induced liver injury TA B L E 3 Reported meta-analysis of liver function/disease in COVID-19 We have also compared our results with previous meta-analysis (Table 3) . 4, 5, [119] [120] [121] [122] [123] [124] [125] This is the first study to report the liver involvement of all adults, pregnant patients and paediatric patients with COVID-19. We have analysed in-depth about the liver involvement in COVID-19, including elevated liver chemistries at initial presentation, during illness and the impact of this on the outcome. We have also reported the elevation in each variable of liver function tests, that is, AST, ALT, bilirubin, albumin, ALP, GGT and prolongation in PT. We also reported the incidence of DILI and the implicated drugs from the available data. Elevated liver chemistries at initial presentation or during illness is an important marker of disease severity.

Serum albumin, a negative acute phase reactant, also indicates severe disease. Liver injury is more common in COVID-19 than non-COVID-19 infections. 23, 126 Liver biopsy in COVID-19 is documented to show moderate microvesicular steatosis with mild lobular and portal activity. 90, 127 SARS-CoV-2 enters cells through the angiotensin-converting enzyme 2 (ACE2) receptor. 128 The second mechanism for liver injury is the cytokine storm, which leads to a surge in inflammatory cytokines and affects the liver. 130 

(Ang II) is intriguing. 134 The ACE2 receptor facilitates the entry of the SARS-CoV-2 into type 2 pneumocytes. After endocytosis of the viral complex, ACE2 is downregulated, which results in unopposed angiotensin II accumulation and worsening systemic complications. 134 In a small recent study, patients with COVID-19 appeared to have elevated levels of plasma Ang II, which were in turn, correlated with total viral load and degree of lung injury. 30 Recombinant ACE2 infusion is proven to reduce disease severity by decreasing Ang II along with increasing ACE2 levels in respiratory viral infection. 135

Increased renin-angiotensin-aldosterone system (RAAS) activity is involved in the pathogenesis of various complications in patients with liver cirrhosis. As the liver disease progresses and worsens, the alternate pathway of the renin-angiotensin system is activated, resulting in a decrease in Ang II and a rise in ACE2. 136, 137 ACE2 activity is upregulated more than twofold in cirrhotic subjects. 137 ACE2 upregulation contributes to splanchnic vasodilatation by degrading Ang II. 137 Increased ACE2 and low Ang II is responsible for increased splanchnic vasodilatation and worsening systemic haemodynamics in cirrhosis. 136, 137 Although the prevalence of CLD in COVID-19 is low, we wonder whether high ACE2 and low Ang II reduces the severity of SARS-CoV-2 in advanced cirrhotic patients. Though this is highly speculative, more data is required to assess the outcomes of advanced liver disease patients with COVID-19. We concur with the recent review, which suggested that patients with CLD are not at greater risk for acquiring the infection based on our meta-analysis. 138 However, we recommend for further focused research on the effect of existing liver-related comorbidities on treatment and outcome of COVID-19.

The main limitation of this meta-analysis is the high heterogeneity in the published articles. The lack of uniformity in classifying the liver disease to compensated or decompensated liver disease or chronic hepatitis in the included studies may limit the generalisability of our findings in pre-existing CLD patients. We also did not analyse the data on liver transplant recipients as it is still evolving. There are some reports of increased mortality in liver transplant recipients due to post-transplant metabolic complications which might outweigh immunosuppression as a risk factor for the development of severe COVID-19 disease. 139, 140 Conversely, some authors have suggested the absence of the role of comorbidities in predicting outcomes of COVID-19 in transplant recipients. 141 Elevated liver chemistries should be uniformly defined in COVID-19, and the details of outcomes of liver disease patients should be appraised separately.

To date, this is the largest systematic review done on pre-existing CLD as well as elevated liver chemistries in COVID-19. We have extensively analysed all groups of the population, including paediatric and pregnant patients detailing the effect of elevated liver chemistries on their outcomes. This is also the first comprehensive review to analyse the effects of drugs, namely remdesvir, lopinavir/ritonavir on hepatic injury in patients with SARS-CoV-2 infection.

Declaration of personal interest: None. 

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Kidney disease is associated with in-hospital death of patients with COVID-19

European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

Coronavirus disease 2019 and prevalence of chronic liver disease: a meta-analysis

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group

COVID-19: abnormal liver function tests

Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)

Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the

Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS)

A principal component analysis is conducted for a case series quality appraisal checklist

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series

Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia

A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China

Clinical characteristics of coronavirus disease 2019 in China

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: a retrospective single center analysis

Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu province: a multicenter descriptive study

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Clinical features of 69 cases with coronavirus disease

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis

Clinical progression of patients with COVID-19 in Shanghai

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

Clinical outcomes in 55 patients with severe acute respiratory syndrome coronavirus 2 who were asymptomatic at hospital admission in Shenzhen

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center

Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study

Analysis of 92 deceased patients with COVID-19

Epidemiologic and clinical characteristics of 26 cases of COVID-19 arising from patient-to-patient transmission in Liaocheng, China

Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha

Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis

Clinical and immunological features of severe and moderate coronavirus disease 2019

Coronavirus disease 2019 in the perioperative period of lung resection: a brief report from a single thoracic surgery department in Wuhan, People's Republic of China

The different clinical characteristics of corona virus disease cases between children and their families in China -the character of children with COVID-19

Clinical characteristics of patients hospitalized with coronavirus disease

A comparative-descriptive analysis of clinical characteristics in 2019-coronavirus-infected children and adults

Clinical and CT features of early stage patients with COVID-19: a retrospective analysis of imported cases in

Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan

Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients

A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan

Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Clinical features of COVID-19-related liver damage

Evaluation of hepatic enzymes changes and association with prognosis in COVID-19 patients

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Evolution of CT findings in patients with mild COVID-19 pneumonia

Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in

Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area

Clinical and computed tomographic (CT) images characteristics in the patients with COVID-19 infection: What should radiologists need to know?

Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia

Clinical and transmission characteristics of covid-19 -a retrospective study of 25 cases from a single thoracic surgery department

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

Covid-19 in critically ill patients in the Seattle region -case series

Clinical characteristics of COVID-19 in children compared with adults in Shandong Province

Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional multicenter study

Sixty-eight consecutive patients assessed for COVID-19 infection: Experience from a UK Regional infectious diseases Unit. Influenza Other Respir Viruses

Clinical and autoimmune characteristics of severe and critical cases of COVID-19

Clinical analysis of 150 cases of 2019 novel coronavirus infection in Nanyang City

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan, China

Epidemiological and clinical features of 125 hospitalized patients with COVID-19 in

Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings

Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China

Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China

Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Clinical features of 85 fatal cases of COVID-19 From Wuhan: a retrospective observational study

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients

Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan

SARS-CoV-2 viral load in clinical samples of critically ill patients

Diabetes is a risk factor for the progression and prognosis of COVID-19

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Baseline Characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang

SARS-CoV-2 infection in children

Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia

Detection of Covid-19 in children in early january 2020 in Wuhan, China

Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study

A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features

Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults

Novel coronavirus infection in children outside of Wuhan, China

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha

Clinical characteristics of children with coronavirus disease 2019 in Hubei, China

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

Incidence of adverse drug reactions in covid-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System

Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Compassionate use of remdesivir for patients with severe Covid-19

Liver injury is associated with severe Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of retrospective studies

AGA Institute rapid review of the GI and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19

COVID-19, MERS and SARS with concomitant liver injury-systematic review of the existing literature

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: a systematic review and meta-analysis

Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis

COVID-19 and Liver dysfunction: a systematic review and meta-analysis of retrospective studies

Liver injury during highly pathogenic human coronavirus infections

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

A pathological report of three COVID-19 cases by minimal invasive autopsies

COVID-19: consider cytokine storm syndromes and immunosuppression

Novel coronavirus pneumonia-related liver injury: etiological analysis and treatment strategy

Endothelial cell infection and endotheliitis in COVID-19

Liver and COVID 19 infection: a very preliminary lesson learnt from histological post-mortem findings in 48 patients

Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Activation of the alternate renin-angiotensin system correlates with the clinical status in human cirrhosis and corrects post liver transplantation

Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2

Review article: COVID-19 and liver disease -what we know on 1st

COVID-19 in longterm liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

COVID-19 in solid organ transplant recipients: initial report from the US epicenter

Determining risk factors for mortality in liver transplant patients with COVID-19

Additional supporting information will be found online in the Supporting Information section.